Robert Marchesani

Försäkringsaktiebolaget Skandia, part of the Old Mutual Group, is a supplier of solutions for financial security and long-term savings. The company was founded in 1855 and is headquartered in Stockholm, Sweden.

Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life.

SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston.

EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed.

Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care.

Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The company is based in Paris, France. The CEO of the French company is Alain Herrera.

Alain Oncologie Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Ad Bio Consulting provides business and management consulting services. The private company is based in Paris, France. The CEO of the French company is Alain Herrera.

Högkullen AB engages in the owning, acquiring, managing, and building of real estate. It provides municipalities, counties, and individual healthcare companies with different forms of group, service, and psychiatric housing services. The company was founded in 1991 and is headquartered in Gothenburg, Sweden.

International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Epicyt Pharma AB is a Swedish pharmaceutical research company that was founded in 2016 by Ville Wallenius and Lars Fändriks. The company is based in Mölndal, Sweden. Epicyt Pharma develops the drug candidate BAFA.

Mindforce Game Lab AB creates games for people with medical conditions, called Playtients™, to help them develop healthy habits. The games are designed to act as companions on the journey to better health and are created by bringing together leading life scientists and top game designers. The CEO of the Swedish company is Anders Rabbe.

Göteborg & Co. is a private company based in Gothenburg, Sweden. The Swedish company operates as the official visitor guide for Gothenburg, providing information on attractions, hotels, restaurants, and other places worth visiting in the city. The CEO of the company is Peter Grönberg.

Johanneberg Science Park AB is a private company based in Gothenburg, Sweden that works to bring together various actors to discuss and be inspired by test beds, development, business models, and collaboration opportunities. The Swedish company is currently working on a project consortium to investigate the energy needs of electrified vehicles and machinery, such as cars, buses, and excavators, and how they can be met through local energy production, energy storage, and the power grid. Additionally, they are collaborating with Innovatum Science Park to coordinate their efforts.

Puls AB is a Swedish company that specializes in sewage, industrial, and environmental services. Puls is located in Staffanstorp, Sweden and is known as the largest player in va maintenance in southern Sweden. The private company offers on-call assistance for a range of issues, including emergency stops in the drain and remediation after accidents. The company provides services such as sewage cleaning, wastewater flushing, and water blasting to clean tanks, cisterns, sheet metal, boat hulls, and more in an environmentally friendly manner. The company has a team of talented employees who specialize in water and wastewater services for tenant-owner associations, offering maintenance and emergency measures.

Hammars Bryggeri AB engages in brewery operations. It produces a wide range of soft drinks, water, and other cider beverages. The company was founded in 1904 and is headquartered in Hammar, Sweden.

Innoext AB provides management consulting services. The private company is based in Västra Frölunda, Sweden. Jan Birger Fredrik Toernell has been the CEO of the Swedish company since 2011.

Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden.

Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden.

Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden.

Oncorena AB develops a novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies in humans. The company was founded in 2011 and is headquartered in Helsingborg, Sweden.

Baricol Bariatrics AB develops, produces, and sells customized products and services for people who have undergone obesity surgery. The firm offers vitamins and minerals. Its customer include medical experts such as doctors and dieticians and people with long experience in the pharmaceutical industry. The company is headquartered in Gothenburg, Sweden.

Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015.